Skip to main content

ERRATUM article

Front. Vet. Sci., 18 January 2023
Sec. Veterinary Pharmacology and Toxicology
Volume 10 - 2023 | https://doi.org/10.3389/fvets.2023.1136968

Erratum: Pharmacokinetic studies in elasmobranchs: Meloxicam administered at 0.5 mg/kg using intravenous, intramuscular, and oral routes to nursehound sharks (Scyliorhinus stellaris)

This article is an erratum on:

  1. Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nursehound Sharks (Scyliorhinus stellaris)

    1. Read original article
\nFrontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Pharmacokinetic studies in elasmobranchs: Meloxicam administered at 0.5 mg/kg using intravenous, intramuscular, and oral routes to nursehound sharks (Scyliorhinus stellaris)

by Morón-Elorza, P., Rojo-Solís, C., Álvaro-Álvarez, T., Valls-Torres, M., García-Párraga, D., and Encinas, T. (2022). Front. Vet. Sci. 9:845555. doi: 10.3389/fvets.2022.845555

Due to a production error, there was a spelling error in the title “Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nusehound Sharks (Scyliorhinus stellaris)”. The correct title is “Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nursehound Sharks (Scyliorhinus stellaris)”.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: meloxicam, shark, chondrichthyan, pharmacology, pharmacokinetics, non-steroidal anti-inflammatory drug (NSAID), half-life (T1/2)

Citation: Frontiers Production Office (2023) Erratum: Pharmacokinetic studies in elasmobranchs: Meloxicam administered at 0.5 mg/kg using intravenous, intramuscular, and oral routes to nursehound sharks (Scyliorhinus stellaris). Front. Vet. Sci. 10:1136968. doi: 10.3389/fvets.2023.1136968

Received: 03 January 2023; Accepted: 03 January 2023;
Published: 18 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, yes production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.